Table 3.
Diagnostic performances of the 3-gene signature set, AFB and T-SPOT in the Biomarker Application Cohort.
| Tests | Sensitivity%, (n/N) 95% CI | Specificity%, (n/N) 95% CI | PPV%, (n/N) 95% CI | NPV%, (n/N) 95% CI | Accuracy, (n/N) 95% CI |
|---|---|---|---|---|---|
| AFB | 44.1 (30/68) | 97.5 (77/79) | 93.8 (30/32) | 67.0 (77/115) | 73.5 (108/147) |
| 32.9–55.9 | 90.7–99.8 | 78.8–99.3 | 57.9–74.9 | 65.8–79.9 | |
| T-SPOT | 86.8 (59/68) | 72.2 (57/79) | 72.8 (59/81) | 86.3 (57/66) | 78.9 (116/147) |
| 76.5–93.1 | 61.4–80.9 | 62.2–81.4 | 75.9–92.9 | 71.6–84.8 | |
| 3-gene set | 82.4 (56/68) | 92.4 (73/79) | 90.3 (56/62) | 85.9 (73/85) | 87.8 (129/147) |
| 71.5–89.8 | 84.1–96.8 | 80.1–95.8 | 76.8–91.9 | 81.4–92.2 | |
| 3-gene set+AFB | 89.7 (61/68) | 91.1 (72/79) | 89.7 (61/68) | 91.1 (72/79) | 90.5 (133/147) |
| 80.0–95.2 | 82.6–95.9 | 79.9–95.2 | 82.6–95.9 | 84.5–94.4 |
PPV, positive predictive value; NPV, negative predictive value.
3-gene set: 3-gene signature set including TNFRSF10C, A2ML1, and EBF3.
3-gene set test was combined with AFB in a serial manner such that a positive result was obtained when either of the test results was positive and a negative result was assigned when both test results were negative.